Expression of BRAF protein in patients with papillary thyroid carcinoma and clinical significance of the research / 中国现代普通外科进展

Objective:To explore the Papillary thyroid carcinoma(PTC) in patients with the expression of BRAF protein and correlation with clinical indicators.Methods:During the selection from June 2015 to June 2016 in our hospital diagnosis and treatment of 120 patients with PTC as the observation group,the other choice during the same period in our hospital make a diagnosis and give treatment of PCT 57 cases as control group,patients with thyroid cancer by immunohistochemical method to detect mutated BRAF protein expression in two groups of patients,and analyze the BRAF protein positive expression and the correlation of PTC clinical indicators.Results:Observation group of patients BRAF protein positive rate was 74.17％,the negative rate was 25.83％,control group patients BRAF protein positive rate was 7.02％,the negative rate was 92.98％,the comparison between groups have significant statistical difference(P＜0.01);Age≤45 years,diameter of tumor＞1 cm,TNM staging for Ⅲ ～Ⅳ stage of PTC patients of BRAF protein positive rate were 96.43％,82.35％,95.65％,significantly higher than the age＞45 years,tumor diameter＜1cm,TNM staging for Ⅰ ～ Ⅱ stage were 67.39％,63.46％,69.07％,and the corresponding comparison have significant statistical difference(P＜0.05).Conclusion:PTC mutated BRAF protein positive rate was significantly higher in patients with non PTC thyroid cancer patients,patients with PTC BRAF protein positive expression related to age,tumor diameter and tumor stage.

Análisis molecular del cáncer de colon esporádico / Molecular analysis of sporadic colon cancer

Background: In Chile, colorectal cancer (CRC) is often diagnosed in late stages. Thus, surgical treatment must be complemented with chemotherapy. KRAS mutations and microsatellite instability have been detected in these tumors. However, the response to treatment in patients without KRAS mutations varies and requires a better understanding. Aim: To determine the frequency and distribution of somatic point mutations in KRAS, BRAF and PIK3CA genes and microsatellite instability status (MSI) in patients with colon cancer (CC). Material and Methods: A prospective observational study of patients undergoing surgery for colon cancer. Tumor-derived DNA was analyzed by polymerase chain reaction (PCR) for the most frequent mutations of KRAS, BRAF and PIK3CA. PCR was also used to analyze MSI. Results: Fifty-eight patients with sporadic CC were analyzed, 16 showed KRAS mutations (G12R, G12D, G12V, G13D) and out of the 42 patients that did not show any mutation, 10 had mutations in BRAF (V600E) and PIK3CA (E542K, E545D, E545K, Q546E, H1047R). BRAF mutations alone or in combination with PIK3CA mutations were observed in 27% of high MSI tumors and in 2% of tumors without instability (p < 0.049). A higher percentage of high MSI tumors were located in the right colon (p < 0.001), and showed BRAF mutation (p < 0.020). Conclusions: The highest percentage of high MSI and BRAF mutations was observed in the right colon. Therefore, this study suggests the presence of different molecular features between right and left colon tumors that should be considered when defining the therapeutic management.

Mutations of the BRAF Gene in Papillary Thyroid Carcinoma in a Korean Population

The B-type Raf kinase (BRAF) protein is a serine/threonine kinase that has an important role in cellular proliferation, differentiation, and programmed cell death. The BRAF gene has been recently found to be mutated in human carcinomas, predominantly in malignant melanoma. The aim of this study was to investigate the frequency of the BRAF mutation in papillary thyroid carcinoma (PTC) of Koreans through direct DNA sequencing of the polymerase chain reaction (PCR) - amplified exon 15 with clinicopathological features. Seventy paraffin-embedded conventional papillary carcinomas in the thyroid gland were evaluated. The BRAF missense mutation at V599E was found in 58 of 70 PTCs (83%). The frequency of our series was much higher than the frequencies of other PTC series (36 - 69%). The frequency of nodal metastasis was also significantly higher in the BRAF mutation group (p= 0.048). These results suggest that the BRAF mutation is involved in the carcinogenesis in most conventional PTCs, especially those occurring in Koreans, and this is a potentially valuable marker for the evaluation of prognosis of patients with PTC. These findings support the specific inhibitors of BRAF being promising targets for the disease outcome.